트라코마 치료제 시장 규모, 점유율, 성장 분석 : 치료별, 약물 종류별, 투여 경로별, 연령별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Trachoma Treatment Market Size, Share, and Growth Analysis, By Treatment (Medication, Surgery), By Drug Class (Macrolides, Tetracycline), By Route of Administration, By Age-group, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1770771
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 07월
페이지 정보:영문 188 Pages
라이선스 & 가격 (부가세 별도)
한글목차
트라코마 치료제 세계 시장 규모는 2023년에 5억 3,020만 달러로 평가되었으며, 예측 기간(2025-2032년) 동안 CAGR 7.1%로, 2024년 5억 6,784만 달러에서 2032년에는 9억 8,298만 달러로 성장할 전망입니다.
트라코마 치료제 시장은 아프리카, 아시아, 라틴아메리카를 중심으로 한 신흥국 지역의 높은 유병률에 힘입어 크게 성장하고 있습니다. 정부의 노력과 국제적인 자금 지원의 증가로 집단 투약과 공중보건 캠페인을 통한 퇴치 활동이 가속화되고 있습니다. 아지트로마이신과 같은 항생제에 대한 접근성이 향상되고, 종종 기부 프로그램을 통해 제공되면서 치료 효과를 더욱 높이고 있습니다. 또한, 인식 개선과 위생 교육 노력은 예방과 재감염률을 낮추는데 중요한 역할을 하고 있습니다. 하지만, 열악한 의료 인프라, 열악한 위생 환경, 기부자 지원에 대한 의존도, 특정 집단의 낮은 인식 등의 문제로 인해 원격지에서의 적시 치료와 지속적인 질병 퇴치 활동을 방해하고 있습니다. 이러한 문제를 해결하는 것이 지속적인 시장 확대에 필수적입니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
기술 분석
사례 연구
규제 분석
트라코마 치료제 시장 규모 : 치료별 & CAGR(2025-2032년)
시장 개요
약
수술
기타
트라코마 치료제 시장 규모 : 약물 종류별 & CAGR(2025-2032년)
시장 개요
매크로라이드
테트라사이클린
안과용 항감염제
설폰아미드
트라코마 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)
시장 개요
경구
외용
트라코마 치료제 시장 규모 : 연령별 & CAGR(2025-2032년)
시장 개요
아동
성인
노인
트라코마 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)
시장 개요
병원 약국
소매 약국
온라인 약국
트라코마 치료제 시장 규모 : 지역별 & CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
최근의 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년비 비교(2022-2024년)
주요 기업 개요
F. Hoffmann-La Roche Ltd.(Switzerland)
Mylan N.V.(US)
Teva Pharmaceutical Industries Ltd.(Jerusalem)
Sanofi(France)
Pfizer Inc.(US)
GlaxoSmithKline plc(UK)
Novartis AG(Switzerland)
Bayer AG(Germany)
Eli Lilly and Company(US)
Merck & Co., Inc.(US)
Allergan(Ireland)
AstraZeneca(UK)
AbbVie Inc.(US)
Johnson & Johnson Private Limited(US)
Cipla Inc.(US)
Bausch Health Companies Inc.(Canada)
Abbott(US)
Fresenius Kabi AG(Germany)
결론과 제안
ksm
영문 목차
영문목차
Global Trachoma Treatment Market size was valued at USD 530.2 million in 2023 and is poised to grow from USD 567.84 million in 2024 to USD 982.98 million by 2032, growing at a CAGR of 7.1% during the forecast period (2025-2032).
The trachoma treatment market is experiencing significant growth, driven by the high prevalence of the disease in developing regions, especially Africa, Asia, and Latin America. Increased government initiatives and international funding have accelerated eradication efforts through mass medication and public health campaigns. Improved access to antibiotics like azithromycin, often provided through donation programs, further supports treatment availability. Moreover, rising awareness and hygiene education initiatives play a vital role in prevention and reducing reinfection rates. However, challenges such as inadequate healthcare infrastructure, poor sanitation, reliance on donor aid, and low awareness in certain populations hinder timely treatment and ongoing disease control efforts in remote areas. Addressing these issues is crucial for sustained market advancement.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Trachoma Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Trachoma Treatment Market Segments Analysis
Global Trachoma Treatment Market is segmented by Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel and region. Based on Treatment, the market is segmented into Medication, Surgery and Others. Based on Drug Class, the market is segmented into Macrolides, Tetracycline, Ophthalmic anti-infective and Sulfonamides. Based on Route of Administration, the market is segmented into Oral and Topical. Based on Age-group, the market is segmented into Children, Adults and Geriatric. Based on Distribution Channel, the market is segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Trachoma Treatment Market
The Global Trachoma Treatment market is significantly driven by the high prevalence of trachoma in many developing countries, especially in certain areas of Africa and Asia. Factors such as overcrowded living conditions, poor sanitation, and limited access to clean water exacerbate the issue, leading to a continual need for effective treatment options. This ongoing health challenge necessitates the implementation of extensive intervention programs, which in turn amplifies the demand for trachoma treatment products across these regions. As a result, the intersection of these elements plays a crucial role in propelling the growth and penetration of the treatment market globally.
Restraints in the Global Trachoma Treatment Market
The global trachoma treatment market faces significant constraints due to the inadequate healthcare infrastructure prevalent in many trachoma-endemic regions. This poor infrastructure hampers crucial aspects like diagnosis, treatment implementation, and patient follow-up. A lack of trained healthcare personnel, substandard medical facilities, and ineffective logistical systems greatly hinder the execution of mass treatment initiatives. Such barriers delay the delivery of interventions, reduce the coverage of treatment efforts, and diminish the effectiveness of public health campaigns aimed at eradicating the disease. Consequently, these factors collectively restrain the overall growth and development of the trachoma treatment market on a global scale.
Market Trends of the Global Trachoma Treatment Market
The Global Trachoma Treatment market is witnessing a transformative trend driven by AI-driven mobile diagnostics, which promise to redefine early detection and screening practices. These innovative, technology-enhanced applications are pivotal in suburban and under-resourced areas, streamlining the process of diagnosing trachoma while reducing dependency on specialized ophthalmic professionals. Consequently, this advancement enables extensive population screenings, enhancing both treatment accuracy and accessibility. As a result, healthcare systems can leverage real-time data analytics for improved surveillance models and informed decision-making, ultimately leading to more effective and efficient management of trachoma on a global scale. This trend signals significant growth potential in the market.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Case Studies
Regulatory Analysis
Global Trachoma Treatment Market Size by Treatment & CAGR (2025-2032)
Market Overview
Medication
Surgery
Others
Global Trachoma Treatment Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Macrolides
Tetracycline
Ophthalmic anti-infective
Sulfonamides
Global Trachoma Treatment Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Topical
Global Trachoma Treatment Market Size by Age-group & CAGR (2025-2032)
Market Overview
Children
Adults
Geriatric
Global Trachoma Treatment Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital pharmacy
Retail pharmacy
Online pharmacy
Global Trachoma Treatment Market Size & CAGR (2025-2032)
North America (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
US
Canada
Europe (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
